Granisetron (Kytril) suppresses methotrexate-induced nausea and vomiting among patients with inflammatory arthritis and is superior to prochlorperazine (Stemetil)

Rheumatology

Volumn 38, Issue 3, 1999, Pages 280-282

  Devlin, J ^a   Wagstaff, K ^a   Arthur, V ^a   Emery, P ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Arthritis; Granisetron; Methotrexate induced; Nausea; Suppression; Vomiting

Indexed keywords

GRANISETRON; METHOTREXATE; PROCHLORPERAZINE; PROCHLORPERAZINE MALEATE;

ARTHRITIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; NAUSEA; PATIENT SATISFACTION; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; SCORING SYSTEM; SINGLE BLIND PROCEDURE; VOMITING;

ANTIEMETICS; ARTHRITIS; GRANISETRON; HUMANS; METHOTREXATE; NAUSEA; PROCHLORPERAZINE; SINGLE-BLIND METHOD; VOMITING;

EID: 0032752395     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/38.3.280     Document Type: Article

References (18)

1. Wilske KR. Inverting the therapeutic pyramid: observations and recommendations on new directions in rheumatoid arthritis therapy based on the author's experience. Semin Arthritis Rheum 1993;23:11-8.
2. Furst DE. Methotrexate: new mechanisms and old toxicities. Agents Actions 1993;44 (suppl.):131-7.
3. Alarcon GS, Tracy IC, Strand GM, Singh K. Macaluso M. Survival and drug discontinuation analyses in a large cohort of methotrexate treated rheumatoid arthritis patients. Ann Rheum Dis 1995;54:708-12.
4. Jacobson SJ, Shore RW, Greenberg M, Spielberg SP. The efficacy and safety of granisetron in pediatric cancer patients who had failed standard antiemetic therapy during anticancer chemotherapy. Am J Pediatr Hematol-Oncol 1994;16:231-5.
5. Yarker YE, McTavish D. Granisetron. An update of its therapeutic use in nausea and vomiting induced by antineoplastic therapy. Drugs 1994;48:761-93.
6. Nodoushani M. Granisetron. Conn Med 1995;59:209-11.
7. Anonymous. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. The Italian Group for Antiemetic Research. N Engl J Med 1995;332:1-5.
8. Aapro MS, Kirchner V, Terrey JP. The incidence of anticipatory nausea and vomiting after repeat cycle chemotherapy: the effect of granisetron. Br J Cancer 1994;69:957-60.
9. Giordano J, Rogers LV. Peripherally administered serotonin 5-HT3 receptor antagonists reduce inflammatory pain in rats. Eur J Pharmacol 1989;170:83-6.
10. Ferrari MD. 5-HT3 receptor antagonists and migraine therapy. J Neurol 1991;238:S53-6.
11. Hrycaj P, Stratz T, Mennet P, Müller W. Pathogenetic aspects of responsiveness to ondansetron (5-hydroxytryptamine type three receptor antagonist) in patients with primary fibromyalgia syndrome-a preliminary study. J Rheumatol 1996;23:1418-23.
12. Dijkmans BAC. Folate supplementation and methotrexate. Br J Rheumatol 1995;34:1172-4.
13. Joyce DA, Will RK, Hoffman DM, Laing B, Blackburn SJ. Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administration of folk acid. Ann Rheum Dis 1991;50:913-4.
14. Shiroky JB, Neville C, Esdaile JM. Low dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis. Results of a multi-centre randomized, double-blind, placebo controlled trial. Arthritis Rheum 1993;36:795-803.
15. Hanrahan PS, Russell AS. Concurrent use of folinic acid and methotrexate in rheumatoid arthritis. J Rheumatol 1988;15:1078-80.
16. Buckley LM, Vacek PM, Cooper SM. Administration of folinic acid after low dose methotrexate in patients with rheumatoid arthritis. J Rheumatol 1990;17:1158-61.
17. Lubeck DP, Spitz PW, Fries JF, Wolfe F, Mitchell DM, Roth SH. A multicenter study of annual health service utilization and costs in rheumatoid arthritis. Arthritis Rheum 1986;29:488-93.
18. Liang MH, Larson M, Thompson M, Eaton H, McNamara E, Katz R, Taylor J. Costs and outcomes in rheumatoid arthritis and osteoarthritis. Arthritis Rheum 1984;27:522-9.